QUOTE AND NEWS
StreetInsider.com  Apr 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Arena+Pharma+%28ARNA%29+Reports+Launch+of+National+Belviq+Ad+Campaign/9376431.html for the full story.
SeekingAlpha  Apr 11  Comment 
By Spencer Osborne: It is certainly an interesting time to be an investor in Arena Pharmaceuticals (ARNA). The company is about 10 months into its launch of the anti-obesity drug Belviq and the equity has taken several lumps along the way. The...
SeekingAlpha  Apr 4  Comment 
By Spencer Osborne: Sales of the Arena Pharmaceuticals (ARNA) anti-obesity drug Belviq have closed out the quarter on a positive note. Sales improved throughout the quarter and are pacing well ahead of the previous quarter. Though this week's...
SeekingAlpha  Mar 28  Comment 
By Spencer Osborne: While the Arena (ARNA) equity may not have been too exciting of late, there are some interesting developments about to begin. The key here is understanding how they will impact the equity as well as in what time-frame those...
SeekingAlpha  Mar 17  Comment 
By Spencer Osborne: As we head toward the end of the first quarter, and the fiscal year end for Arena's (ARNA) marketing partner Eisai (OTCPK:ESALY), it is appropriate to assess where we are for both companies in terms of the sales for the...
SeekingAlpha  Mar 7  Comment 
By Spencer Osborne: The script numbers for Arena Pharmaceuticals (ARNA) Belviq for the last week in February are in. According to industry tracker IMS, the prescriptions for Belviq came in just under 7,000 and were up just over 6% from the...
SeekingAlpha  Mar 3  Comment 
By Robert Opaluch: Thursday February 27th, Arena Pharmaceuticals (ARNA) reported disappointing sales of their new diet drug BELVIQ. BELVIQ sales came in at the low end of a wide range of estimates. Arena's worldwide sales partner Eisai and Arena...
SeekingAlpha  Feb 28  Comment 
By Spencer Osborne: Arena Pharmaceuticals (ARNA) reported earnings yesterday. Today the news and follow-through will be on prescription sales. As most investors already know, Arena posted a loss for Q4. The revenue from Arena's share Belviq sales...
Benzinga  Feb 28  Comment 
Compugen (NASDAQ: CGEN) shares fell 16.83% to $11.81 in the pre-market trading after the company announced a proposed public offering of ordinary shares. Deckers Outdoor (NASDAQ: DECK) dipped 13.19% to $73.50 after the company expected a Q1...
SeekingAlpha  Feb 28  Comment 
Arena Pharmaceuticals (ARNA) Q4 2013 Results Earnings Conference Call February 27, 2014, 5:00 p.m. ET Executives Jack Lief - Co-Founder, Chairman, President and CEO Craig Audet - SVP, Operations and Head of Global Regulatory Affairs ...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki